AMRS - Amyris finalizes $500M deal for license distribution marketing of two ingredients
- Amyris ( NASDAQ: AMRS ) has completed the negotiation of an agreement worth $500M to license the distribution and marketing of two of the company's ingredients.
- Shares are up ~7% in pre-market trading.
- The deal is expected to close in Q1 2023.
- The other party in the transaction was not named.
- The deal is the third of its kind for Amyris ( AMRS ).
- In January, the company and ImmunityBio ( IBRX ) announced a joint venture for the commercialization of a COVID-19 vaccine .
For further details see:
Amyris finalizes $500M deal for license distribution, marketing of two ingredients